And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. And our agenda is rather modest. We plan to spend time with two of our short people and escort Mrs. Pharmalot to a festive gathering. And what about you? Summer is in full swing, so perhaps this calls for a jaunt to the shore or a lake. You could use the time to exercise outdoors or simply catch up on chores. That rhymes. Well, whatever you do, have a grand time, but be safe. Enjoy and see you soon …
The National Health Service in England agreed to cover a Duchenne muscular dystrophy drug made by PTC Therapeutics, PharmaTimes says. The deal includes an outcomes-based incentive for the company, as well as a mechanism to monitor how well the medicine has actually worked before future funding decisions are made. The application for the same drug, which costs about $288,000 a year, was rejected earlier this year by US regulators.
Meanwhile, Eisai is considering possible legal action to fight delays in the UK health care system that prevent patients from accessing one of its drugs to treat a rare form of cancer, Reuters tells us. Its Lenvima treats a form of thyroid cancer and was approved by the European Commission in May 2015, but will not receive a recommendation from the UK’s National Institute for Health and Care Excellence until at least April 2017.
About the Author Reprints
